Skip to main content

Articles

Page 8 of 65

  1. EGFR-TKI targeted therapy is one of the most effective treatments for lung cancer patients harboring EGFR activating mutations. However, inhibition response is easily attenuated by drug resistance, which is ma...

    Authors: Xueli Tian, Rui Wang, Tingxuan Gu, Fayang Ma, Kyle Vaughn Laster, Xiang Li, Kangdong Liu, Mee-Hyun Lee and Zigang Dong
    Citation: Molecular Cancer 2022 21:193
  2. Circular RNAs (circRNAs) act as gene expression regulators and are involved in cancer progression. However, their functions have not been sufficiently investigated in nasopharyngeal carcinoma (NPC).

    Authors: Yongzhen Mo, Yumin Wang, Yian Wang, Xiangying Deng, Qijia Yan, Chunmei Fan, Shuai Zhang, Shanshan Zhang, Zhaojian Gong, Lei Shi, Qianjin Liao, Can Guo, Yong Li, Guiyuan Li, Zhaoyang Zeng, Weihong Jiang…
    Citation: Molecular Cancer 2022 21:192
  3. In vivo gene editing of somatic cells with CRISPR nucleases has facilitated the generation of autochthonous mouse tumors, which are initiated by genetic alterations relevant to the human disease and progress a...

    Authors: Nastasja Merle, Sabrina Elmshäuser, Florian Strassheimer, Michael Wanzel, Alexander M. König, Julianne Funk, Michelle Neumann, Katharina Kochhan, Frederik Helmprobst, Axel Pagenstecher, Andrea Nist, Marco Mernberger, André Schneider, Thomas Braun, Tilman Borggrefe, Rajkumar Savai…
    Citation: Molecular Cancer 2022 21:191
  4. Anaplastic thyroid carcinoma (ATC) is an extremely malignant type of endocrine cancer frequently accompanied by extrathyroidal extension or metastasis through mechanisms that remain elusive. We screened for th...

    Authors: Zongfu Pan, Tong Xu, Lisha Bao, Xiaoping Hu, Tiefeng Jin, Jinming Chen, Jianqiang Chen, Yangyang Qian, Xixuan Lu, Lu li, Guowan Zheng, Yiwen Zhang, Xiaozhou Zou, Feifeng Song, Chuanming Zheng, Liehao Jiang…
    Citation: Molecular Cancer 2022 21:190
  5. Over the past decade, immune checkpoint inhibitor (ICI) therapy has been established as the standard of care for many types of cancer, but the strategies employed have continued to evolve. Recently, much clini...

    Authors: Roger J. Daly, Andrew M. Scott, Oliver Klein and Matthias Ernst
    Citation: Molecular Cancer 2022 21:189
  6. Lung cancer is one of the fatal cancers worldwide, and over 60% of patients are lung adenocarcinoma (LUAD). Our clinical data demonstrated that DNA methylation of the promoter region of miR-126-3p was upregula...

    Authors: Lu Liang, Huiyu Cen, Jionghua Huang, Aiping Qin, Wenyan Xu, Siran Wang, Zhijun Chen, Lin Tan, Qiqi Zhang, Xiyong Yu, Xin Yang and Lingmin Zhang
    Citation: Molecular Cancer 2022 21:186
  7. Chimeric antigen receptor (CAR) T-cell therapy using brexucabtagene autoleucel (BA) induces remission in many patients with mantle cell lymphoma (MCL), and BA is the only CAR T-cell therapy approved by the FDA...

    Authors: Vivian Changying Jiang, Dapeng Hao, Preetesh Jain, Yijing Li, Qingsong Cai, Yixin Yao, Lei Nie, Yang Liu, Jingling Jin, Wei Wang, Heng-Huan Lee, Yuxuan Che, Enyu Dai, Guangchun Han, Ruiping Wang, Kunal Rai…
    Citation: Molecular Cancer 2022 21:185
  8. Up to 80% of cases of prostate cancer present with multifocal independent tumour lesions leading to the concept of a field effect present in the normal prostate predisposing to cancer development. In the prese...

    Authors: Claudia Buhigas, Anne Y. Warren, Wing-Kit Leung, Hayley C. Whitaker, Hayley J. Luxton, Steve Hawkins, Jonathan Kay, Adam Butler, Yaobo Xu, Dan J. Woodcock, Sue Merson, Fiona M. Frame, Atef Sahli, Federico Abascal, Iñigo Martincorena, G. Steven Bova…
    Citation: Molecular Cancer 2022 21:183
  9. Multiple myeloma (MM) is a heterogeneous disease with different patterns of clonal evolution and a complex tumor microenvironment, representing a challenge for clinicians and pathologists to understand and dis...

    Authors: Yuanzheng Liang, Haiyan He, Weida Wang, Henan Wang, Shaowen Mo, Ruiying Fu, Xindi Liu, Qiong Song, Zhongjun Xia and Liang Wang
    Citation: Molecular Cancer 2022 21:182
  10. Although, micropeptides encoded by non-coding RNA have been shown to have an important role in a variety of tumors processes, there have been no reports on micropeptide in renal cell carcinoma (RCC). Based on ...

    Authors: Mengwei Li, Guangxiang Liu, Xinrong Jin, Hongqian Guo, Sarra Setrerrahmane, Xindi Xu, Tiantian Li, Yunfei Lin and Hanmei Xu
    Citation: Molecular Cancer 2022 21:181
  11. Mesenchymal stem cells (MSCs) are multipotent stromal cells that can be obtained from various human tissues and organs. They can differentiate into a wide range of cell types, including osteoblasts, adipocytes...

    Authors: Zhengjun Lin, Yanlin Wu, Yiting Xu, Guoqing Li, Zhihong Li and Tang Liu
    Citation: Molecular Cancer 2022 21:179
  12. Epidermal growth factor receptor (EGFR) is both a driver oncogene and a therapeutic target in advanced head and neck squamous cell carcinoma (HNSCC). However, response to EGFR treatment is inconsistent and lac...

    Authors: Henrik Schinke, Enxian Shi, Zhongyang Lin, Tanja Quadt, Gisela Kranz, Jiefu Zhou, Hongxia Wang, Julia Hess, Steffen Heuer, Claus Belka, Horst Zitzelsberger, Udo Schumacher, Sandra Genduso, Kristoffer Riecken, Yujing Gao, Zhengquan Wu…
    Citation: Molecular Cancer 2022 21:178
  13. Given that hypoxia is a persistent physiological feature of many different solid tumors and a key driver for cancer malignancy, it is thought to be a major target in cancer treatment recently. Tumor-associated...

    Authors: Ruixue Bai, Yunong Li, Lingyan Jian, Yuehui Yang, Lin Zhao and Minjie Wei
    Citation: Molecular Cancer 2022 21:177
  14. Epigenetic programming during development is essential for determining cell lineages, and alterations in this programming contribute to the initiation of embryonal tumour development. In neuroblastoma, neural ...

    Authors: Carlos Jiménez, Roberta Antonelli, Mariona Nadal-Ribelles, Laura Devis-Jauregui, Pablo Latorre, Carme Solé, Marc Masanas, Adrià Molero-Valenzuela, Aroa Soriano, Josep Sánchez de Toledo, David Llobet-Navas, Josep Roma, Francesc Posas, Eulàlia de Nadal, Soledad Gallego, Lucas Moreno…
    Citation: Molecular Cancer 2022 21:175
  15. Chemoresistance is a major factor contributing to the poor prognosis of patients with pancreatic cancer, and cancer stemness is one of the most crucial factors associated with chemoresistance and a very promis...

    Authors: Yi Zhang, Xiaomeng Liu, Yan Wang, Shihui Lai, Zhiqian Wang, Yudie Yang, Wenhui Liu, Hongquan Wang and Bo Tang
    Citation: Molecular Cancer 2022 21:174
  16. Circular RNAs (circRNAs) mediate the infiltration of tumor-associated macrophages (TAMs) to facilitate carcinogenesis and development of various types of cancers. However, the role of circRNAs in regulating ma...

    Authors: Tao Xie, Du-jiang Fu, Zhi-min Li, Dao-jun Lv, Xian-Lu Song, Yu-zhong Yu, Chong Wang, Kang-jin Li, Baoqian Zhai, Jiacheng Wu, Ning-Han Feng and Shan-Chao Zhao
    Citation: Molecular Cancer 2022 21:173

    The Correction to this article has been published in Molecular Cancer 2023 22:173

  17. Anaplastic large cell lymphoma (ALCL) is an aggressive non-Hodgkin T cell lymphoma commonly driven by NPM-ALK. AP-1 transcription factors, cJUN and JUNb, act as downstream effectors of NPM-ALK and transcriptio...

    Authors: I. Garces de los Fayos Alonso, L. Zujo, I. Wiest, P. Kodajova, G. Timelthaler, S. Edtmayer, M. ZrimÅ¡ek, S. Kollmann, C. Giordano, M. Kothmayer, H. A. Neubauer, S. Dey, M. Schlederer, B. S. Schmalzbauer, T. Limberger, C. Probst…
    Citation: Molecular Cancer 2022 21:172
  18. CDK4/6 inhibitors combined with endocrine therapy has become the preferred treatment approach for patients with estrogen receptor-positive metastatic breast cancer. However, the predictive biomarkers and mecha...

    Authors: Hongnan Mo, Xuefeng Liu, Yu Xue, Hongyan Chen, Shichao Guo, Zhangfu Li, Shuang Wang, Caiming Li, Jiashu Han, Ming Fu, Yongmei Song, Dan Li and Fei Ma
    Citation: Molecular Cancer 2022 21:171
  19. This article has been retracted. Please see the Retraction Notice for more detail: https://0-doi-org.brum.beds.ac.uk/10.1186/s12943-016-0533-3.

    Authors: Zhenyue He, Jun Yi, Xiaolong Liu, Jing Chen, Siqi Han, Li Jin, Longbang Chen and Haizhu Song
    Citation: Molecular Cancer 2022 21:170
  20. Genetic variants associated with acute side effects of radiotherapy in nasopharyngeal carcinoma (NPC) remain largely unknown.

    Authors: Yang Wang, Fan Xiao, Yi Zhao, Chen-Xue Mao, Lu-Lu Yu, Lei-Yun Wang, Qi Xiao, Rong Liu, Xi Li, Howard L. McLeod, Bi-Wen Hu, Yu-Ling Huang, Qiao-Li Lv, Xiao-Xue Xie, Wei-Hua Huang, Wei Zhang…
    Citation: Molecular Cancer 2022 21:169
  21. Hypoxia, a typical hallmark of solid tumors, exhibits an essential role in the progression of colorectal cancer (CRC), in which the dysregulation of long non-coding RNAs (lncRNAs) is frequently observed. Howev...

    Authors: Li Zhou, Jingwen Jiang, Zhao Huang, Ping Jin, Liyuan Peng, Maochao Luo, Zhe Zhang, Yan Chen, Na Xie, Wei Gao, Edouard C. Nice, Jing-Quan Li, Hai-Ning Chen and Canhua Huang
    Citation: Molecular Cancer 2022 21:168
  22. Disappointing clinical efficacy of standard treatment has been proven in refractory metastatic osteosarcoma, and the emerging anti-angiogenic regimens are still in the infantile stage. Thus, there is an urgent...

    Authors: Lingfeng Yu, Hao Zhu, Zhen Wang, Jianhao Huang, Yan Zhu, Gentao Fan, Yicun Wang, Xi Chen and Guangxin Zhou
    Citation: Molecular Cancer 2022 21:167
  23. Acute myeloid leukemia (AML) is a heterogeneous and aggressive blood cancer that results from diverse genetic aberrations in the hematopoietic stem or progenitor cells (HSPCs) leading to the expansion of blast...

    Authors: Yanan Zhai, Prashant Singh, Anna Dolnik, Peter Brazda, Nader Atlasy, Nunzio del Gaudio, Konstanze Döhner, Hartmut Döhner, Saverio Minucci, Joost Martens, Lucia Altucci, Wout Megchelenbrink, Lars Bullinger and Hendrik G. Stunnenberg
    Citation: Molecular Cancer 2022 21:166
  24. Developing a strategy to specifically kill cancer cells without inducing obvious damage to normal cells may be of great clinical significance for cancer treatment. In the present study, we developed a new prec...

    Authors: Junfeng Jiang, Yuanyuan Chen, Li Zhang, Qishu Jin, Liujun Wang, Sha Xu, Kexin Chen, Li Li, Tao Zeng, Xingfei Fan, Tingting Liu, Jiaxi Li, Jinjiang Wang, Chaofeng Han, Fu Gao, Yanyong Yang…
    Citation: Molecular Cancer 2022 21:164
  25. This article has been retracted. Please see the Retraction Notice for more detail: https://0-doi-org.brum.beds.ac.uk/10.1186/s12943-018-0783-3.

    Authors: Xiaomin Fu, Xiaoyan Zhu, Fujun Qin, Yong Zhang, Jizhen Lin, Yuechao Ding, Zihe Yang, Yiman Shang, Li Wang, Qinxian Zhang and Quanli Gao
    Citation: Molecular Cancer 2022 21:161
  26. Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) is the most frequently mutated oncogene, occurring in a variety of tumor types. Targeting KRAS mutations with drugs is challenging because KRAS is considered u...

    Authors: Chunxiao Zhu, Xiaoqing Guan, Xinuo Zhang, Xin Luan, Zhengbo Song, Xiangdong Cheng, Weidong Zhang and Jiang-Jiang Qin
    Citation: Molecular Cancer 2022 21:159
  27. Brother of regulator of imprinted sites (BORIS) is expressed in most cancers and often associated with short survival and poor prognosis in patients. BORIS inhibits apoptosis and promotes proliferation of canc...

    Authors: Yanmei Zhang, Mengdie Fang, Shouye Li, Hao Xu, Juan Ren, Linglan Tu, Bowen Zuo, Wanxin Yao and Guang Liang
    Citation: Molecular Cancer 2022 21:158
  28. This article has been retracted. Please see the Retraction Notice for more detail: https://0-doi-org.brum.beds.ac.uk/10.1186/s12943-019-0981-7.

    Authors: Tong Liu, Xin Zhang, Lutao Du, Yunshan Wang, Xiaoming Liu, Hui Tian, Lili Wang, Peilong Li, Yinghui Zhao, Weili Duan, Yujiao Xie, Zhaowei Sun and Chuanxin Wang
    Citation: Molecular Cancer 2022 21:157
  29. Myeloid and lymphoid malignancies associated with chimeric FGFR1 kinases are the hallmark of stem cell leukemia and lymphoma syndrome (SCLL). In all cases, FGFR1 kinase is constitutively phosphoactivated as a ...

    Authors: Baohuan Cai, Yun Liu, Yating Chong, Stephanie Fay Mori, Atsuko Matsunaga, Hualei Zhang, Xuexiu Fang, Chang-Sheng Chang, John K. Cowell and Tianxiang Hu
    Citation: Molecular Cancer 2022 21:156
  30. Epstein-Barr Virus (EBV)-associated nasopharyngeal carcinoma (NPC) exhibits unusual geographic restriction despite ubiquitous lifelong infection. Screening programs can detect most NPC cases at an early stage,...

    Authors: Jacob A. Miller, Malaya K. Sahoo, Fumiko Yamamoto, ChunHong Huang, Hannah Wang, James L. Zehnder, Quynh-Thu Le and Benjamin A. Pinsky
    Citation: Molecular Cancer 2022 21:154
  31. Cell division cycle 6 (CDC6) has been proven to be associated with the initiation and progression of human multiple tumors. However, it’s role in glioma, which is ranked as one of the common primary malignant ...

    Authors: Feng Wang, Fen Zhao, Li Zhang, Lai Xiong, Qing Mao, Yanhui Liu, Xiaoguang Qiu, Xiang Wang, Lin Shui, Xi Chen, Kexing Ren, Pixian Shui, Qiongwen Zhang, Yifei Deng, Weimin Li, Xiaoqi Xie…
    Citation: Molecular Cancer 2022 21:153
  32. Authors: Sara Donzelli, Mario Cioce, Andrea Sacconi, Francesca Zanconato, Theodora Daralioti, Frauke Goeman, Giulia Orlandi, Simona Di Martino, Vito Michele Fazio, Gabriele Alessandrini, Stefano Telera, Mariantonia Carosi, Gennaro Ciliberto, Claudio Botti, Sabrina Strano, Stefano Piccolo…
    Citation: Molecular Cancer 2022 21:152
  33. Recurrence and chemoresistance constitute the leading cause of death in colorectal cancer (CRC). Thus, it is of great significance to clarify the underlying mechanisms and identify predictors for tailoring adj...

    Authors: Haibo Wang, Wenjing Yang, Qiong Qin, Xiaomei Yang, Ying Yang, Hua Liu, Wenxiu Lu, Siyu Gu, Xuedi Cao, Duiping Feng, Zhongtao Zhang and Junqi He
    Citation: Molecular Cancer 2022 21:151
  34. Long non-coding RNAs (lncRNAs) are implicated in the development of multiple cancers. In our previous study, we demonstrated that HDAC1/4-mediated silencing of microRNA-200b (miR-200b) enhances docetaxel (DTX)...

    Authors: Min Jiang, Feng Qi, Kai Zhang, Xiaofei Zhang, Jingjing Ma, Suhua Xia, Longbang Chen, Zhengyuan Yu, Jing Chen and Dongqin Chen
    Citation: Molecular Cancer 2022 21:150
  35. Emerging evidence indicates that circular RNAs (circRNAs) and m6A RNA methylation participate in the pathogenesis and metastasis of multiple malignancies including hepatocellular carcinoma (HCC). However, it rema...

    Authors: Lianyong Liu, Mingjun Gu, Junhua Ma, Ying Wang, Miao Li, Hui Wang, Xin Yin and Xiangqi Li
    Citation: Molecular Cancer 2022 21:149
  36. The resistance of tumor cells to therapy severely impairs the efficacy of treatment, leading to recurrence and metastasis of various cancers. Clarifying the underlying mechanisms of therapeutic resistance may ...

    Authors: Hong Lin, Yuxi Wang, Pinghan Wang, Fangyi Long and Ting Wang
    Citation: Molecular Cancer 2022 21:148
  37. Long Interspersed Nuclear Element-1 (LINE-1, L1) is increasingly regarded as a genetic risk for lung cancer. Transcriptionally active LINE-1 forms a L1-gene chimeric transcript (LCTs), through somatic L1 retro...

    Authors: Zeguo Sun, Rui Zhang, Xiao Zhang, Yifei Sun, Pengpeng Liu, Nancy Francoeur, Lei Han, Wan Yee Lam, Zhengzi Yi, Robert Sebra, Martin Walsh, Jinpu Yu and Weijia Zhang
    Citation: Molecular Cancer 2022 21:147
  38. Increasing evidence has demonstrated that circular RNAs (circRNAs) are implicated in cancer progression. However, the aberrant expression and biological functions of circRNAs in clear cell renal cell carcinoma...

    Authors: Zhipeng Xu, Shuqiu Chen, Ruiji Liu, Hui Chen, Bin Xu, Weizhang Xu and Ming Chen
    Citation: Molecular Cancer 2022 21:146
  39. Circular RNAs (circRNAs) have been demonstrated to contribute to esophageal cancer progression. CircBCAR3 (hsa_circ_0007624) is predicted to be differentially expressed in esophageal cancer by bioinformatics a...

    Authors: Yong Xi, Yaxing Shen, Donglei Wu, Jingtao Zhang, Chengbin Lin, Lijie Wang, Chaoqun Yu, Bentong Yu and Weiyu Shen
    Citation: Molecular Cancer 2022 21:145

Annual Journal Metrics

  • 2022 Citation Impact
    37.3 - 2-year Impact Factor
    33.1 - 5-year Impact Factor
    5.740 - SNIP (Source Normalized Impact per Paper)
    8.703 - SJR (SCImago Journal Rank)

    2023 Speed
    5 days submission to first editorial decision for all manuscripts (Median)
    91 days submission to accept (Median)

    2023 Usage 
    3,569,666 downloads
    2,070 Altmetric mentions